Global Biosimilars Market Size & Share to 2027
Global Biosimilars Market Size, Trends & Growth Opportunity, By Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Fusion Proteins, Insulin, Monoclonal Antibodies, Erythropoietin, Follitropin, Anticoagulants, and others, by therapy type such as Immunology, Oncology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), By Therapy Type, By Distribution Channel, By Region and Forecast till 2027
Global Biosimilars Market
Biosimilars are highly identical to approved biological drugs. They have similar properties in terms of safety, potency, and efficacy to original biologic products but they have minor differences in clinically inactive components. Regulations for biosimilars play important role in maintaining the viability and balance between reference product and biosimilars product. Various regulatory authorizes like FDA and EMA actively regulate the development and commercialization of biosimilars.
Market Drivers
The rise in number of biosimilar approvals is the key driving factor which is expected to boost the global biosimilars market growth. For instance, in July 2018, the USFDA (U.S. Food and Drug Administration) had introduced a biosimilars action plan to encourage the development of biosimilars. Furthermore, increases in prevalence of chronic diseases like cancer will positively contribute the market growth. For instance, in 2018, as per the NCI (National Cancer Institute) information approximates 1,735,350 new cases of cancer likely to be diagnosed in United States. Moreover, increase in research and development activities as well as government initiatives will fuel the global biosimilars market growth during this forecast period. Many governments are emphasizing on cost-effective drug synthesis. The united Ststes is the popular country with highest health expenditure.
Market Restraints
However, a complexity in manufacturing is the major restraining factor which is expected to hinder the global biosimilars market growth. Also, stringent rules and regulations for development and manufacturing of biosimilars will affect the market growth.
Market Segmentation
Global Biosimilars Market is segmented into drug class such as Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Fusion Proteins, Insulin, Monoclonal Antibodies, Erythropoietin, Follitropin, Anticoagulants, and others, by therapy type such as Immunology, Oncology, Hematology, Hormone Therapy, Metabolic Disorders, and Others. Further, market is segmented into distribution channel such as Hospital Pharmacies, Retail Pharmacies, and Speciality Pharmacies.
Also, Global Biosimilars Market is segmented into is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Market Key Players
Various key players are discussed in this report such as Novartis AG, Pfizer Inc. Celltrion Healthcare Co., Ltd, Teva Pharmaceutical, Biocon Limited, Dr. Reddy's Laboratories, Amgen, Inc.,and Sanofi S.A.
Market Taxonomy
By Drug Class
- Recombinant Human Growth Hormone
- Granulocyte Colony-Stimulating Factor
- Fusion Proteins
- Insulin
- Erythropoietin
- Monoclonal Antibodies
- Follitropin
- Anticoagulants
- Others
- Immunology
- Oncology
- Hematology
- Hormone Therapy
- Metabolic Disorders
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
- What are the Key Opportunities in Global Biosimilars Market?
- What will be the growth rate from 2019 to 2027?
- Which segment/region will have highest growth?
- What are the factors that will impact/drive the Market?
- What is the competitive Landscape in the Industry?
- What is the role of key players in the value chain?
- What are the strategies adopted by key players?
- 1 Introduction
- 1.1 Objective of the Study
- 1.2 Market Definition
- 1.3 Market Scope
- 2 Research Methodology
- 2.1 Data Mining
- 2.2 Validation
- 2.3 Primary Interviews
- 2.4 List of Data Sources
- 3 Executive Summary
- 4 Global Biosimilars Market Outlook
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
- 5 Global Biosimilars Market, By Drug Class
- 5.1 Y-o-Y Growth Comparison, By Drug Class
- 5.2 Global Biosimilars Market Share Analysis, By Drug Class
- 5.3 Global Biosimilars Market Size and Forecast, By Drug Class
- 5.3.1 Recombinant Human Growth Hormone
- 5.3.2 Granulocyte Colony-Stimulating Factor
- 5.3.3 Fusion Proteins
- 5.3.4 Insulin
- 5.3.5 Monoclonal Antibodies
- 5.3.6 Erythropoietin
- 5.3.7 Follitropin
- 5.3.8 Anticoagulants
- 5.3.9 Others
- 6 Global Biosimilars Market, By Therapy Class
- 6.1 Y-o-Y Growth Comparison, By Therapy Class
- 6.2 Global Biosimilars Market Share Analysis, By Therapy Class
- 6.3 Global Biosimilars Market Size and Forecast, By Therapy Class
- 6.3.1 Immunology
- 6.3.2 Oncology
- 6.3.3 Hematology
- 6.3.4 Hormone Therapy
- 6.3.5 Metaboloc Disorders
- 6.3.6 Others
- 7 Global Biosimilars Market, By Distribution Channel
- 7.1 Y-o-Y Growth Comparison, By Distribution Channel
- 7.2 Global Biosimilars Market Share Analysis, By Distribution Channel
- 7.3 Global Biosimilars Market Size and Forecast, By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Specialty Pharmacies
- 8 Global Biosimilars Market, By Region
- 8.1 Global Biosimilars Market Share Analysis, By Region
- 8.2 Global Biosimilars Market Share Analysis, By Region
- 8.3 Global Biosimilars Market Size and Forecast, By Region
- 9 North America Biosimilars Market Analysis and Forecast (2020-2027)
- 9.1 Introduction
- 9.2 North America Biosimilars Market Share Analysis, By Drug Class
- 9.3 North America Biosimilars Market Size and Forecast, By Therapy Class
- 9.4 North America Biosimilars Market Size and Forecast, By Distribution Channel
- 9.5 North America Biosimilars Market Size and Forecast, By Country
- 9.5.1 U.S.
- 9.5.2 Canada
- 9.5.3 Mexico
- 10 EuropeBiosimilars Market Analysis and Forecast (2020-2027)
- 10.1 Introduction
- 10.2 Europe Biosimilars Market Share Analysis, By Drug Class
- 10.3 Europe Biosimilars Market Size and Forecast, By Therapy Class
- 10.4 Europe Biosimilars Market Size and Forecast, By Distribution Channel
- 10.5 Europe Biosimilars Market Size and Forecast, By Country
- 10.5.1 Germany
- 10.5.2 France
- 10.5.3 UK
- 10.5.4 Rest of Europe
- 11 Asia Pacific Biosimilars Market Analysis and Forecast (2020-2027)
- 11.1 Introduction
- 11.2 Asia Pacific Biosimilars Market Share Analysis, By Drug Class
- 11.3 Asia Pacific Biosimilars Market Size and Forecast, By Therapy Class
- 11.4 Asia Pacific Biosimilars Market Size and Forecast, By Distribution Channel
- 11.5 Asia Pacific Biosimilars Market Size and Forecast, By Country
- 11.5.1 China
- 11.5.2 Japan
- 11.5.3 India
- 11.5.4 Rest of Asia Pacific
- 12 Latin America Biosimilars Market Analysis and Forecast (2020-2027)
- 12.1 Introduction
- 12.2 Latin America Biosimilars Market Share Analysis, By Drug Class
- 12.3 Latin America Biosimilars Market Size and Forecast, By Therapy Class
- 12.4 Latin America Biosimilars Market Size and Forecast, By Distribution Channel
- 12.5 Latin America Biosimilars Market Size and Forecast, Country
- 13 Middle East Biosimilars Market Analysis and Forecast (2020-2027)
- 13.1 Introduction
- 13.2 Middle East Biosimilars Market Share Analysis, By Drug Class
- 13.3 Middle East Biosimilars Market Size and Forecast, By Therapy Class
- 13.4 Middle East Biosimilars Market Size and Forecast, By Distribution Channel
- 13.5 Middle East Biosimilars Market Size and Forecast, By Country
- 14 Competitive Analysis
- 14.1 Competition Dashboard
- 14.2 Market share Analysis of Top Vendors
- 14.3 Key Development Strategies
- 15 Company Profiles
- 15.1 Novartis AG
- 15.1.1 Overview
- 15.1.2 Offerings
- 15.1.3 Key Financials
- 15.1.4 Business Segment & Geographic Overview
- 15.1.5 Key Market Developments
- 15.1.6 Key Strategies
- 15.2. Pfizer Inc
- 15.2.1 Overview
- 15.2.2 Offerings
- 15.2.3 Key Financials
- 15.2.4 Business Segment & Geographic Overview
- 15.2.5 Key Market Developments
- 15.2.6 Key Strategies
- 15.3. Celltrion Healthcare Co., Ltd
- 15.3.1 Overview
- 15.3.2 Offerings
- 15.3.3 Key Financials
- 15.3.4 Business Segment & Geographic Overview
- 15.3.5 Key Market Developments
- 15.3.6 Key Strategies
- 15.4 Teva Pharmaceutical
- 15.4.1 Overview
- 15.4.2 Offerings
- 15.4.3 Key Financials
- 15.4.4 Business Segment & Geographic Overview
- 15.4.5 Key Market Developments
- 15.4.6 Key Strategies
- 15.5 Biocon Limited
- 15.5.1 Overview
- 15.5.2 Offerings
- 15.5.3 Key Financials
- 15.5.4 Business Segment & Geographic Overview
- 15.5.5 Key Market Developments
- 15.5.6 Key Strategies
- 15.6 Dr. Reddy's Laboratories
- 15.6.1 Overview
- 15.6.2 Offerings
- 15.6.3 Key Financials
- 15.6.4 Business Segment & Geographic Overview
- 15.6.5 Key Market Developments
- 15.6.6 Key Strategies
- 15.7 Amgen, Inc
- 15.7.1 Overview
- 15.7.2 Offerings
- 15.7.3 Key Financials
- 15.7.4 Business Segment & Geographic Overview
- 15.7.5 Key Market Developments
- 15.7.6 Key Strategies
- 15.8 Sanofi S.A.
- 15.8.1 Overview
- 15.8.2 Offerings
- 15.8.3 Key Financials
- 15.8.4 Business Segment & Geographic Overview
- 15.8.5 Key Market Developments
- 15.8.6 Key Strategies
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook